Glassman Wealth Services’s Clovis Oncology, Inc. CLVS Stock Holding History

Glassman Wealth Services’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4	Closed	–	–	966
2017 Q4	$0	Buy	+4	New	+$280	﹤0.01%	829

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Glassman Wealth Services's CLVS Position: Q1 2018 in Review

Glassman Wealth Services sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 4 shares.

Glassman Wealth Services first reported a position in CLVS in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

Glassman Wealth Services reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
Glassman Wealth Services sold 4 Clovis Oncology, Inc. shares in Q1 2018.
Glassman Wealth Services first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 1 quarter.
Glassman Wealth Services's Clovis Oncology, Inc. position peaked at $0 in Q4 2017.
229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Glassman Wealth Services's 13F filing for Q1 2018, filed 1 May 2018.